Opinion|Videos|March 28, 2025
The Recent Updates in the Management Advanced NSCLC with HER2 or NRG1 Alterations
Panelists discuss how emerging data on novel HER2-targeted agents, including Beamion LUNG-1 (zongertinib) and SOHO-1 (BAY 2927088), show promise for advanced non–small cell lung cancer (NSCLC). Additionally, the eNRGy trial and FDA approval of zenocutuzumab for NRG1 fusion–positive non–small cell lung cancer (NSCLC) offers new treatment avenues. Patient selection will depend on genetic profiling and treatment efficacy.
Advertisement
Video content above is prompted by the following:
- What are your thoughts on the emerging data surrounding novel HER2-targeted agents, and how may they impact the future treatment landscape for NSCLC?
- Beamion LUNG-1 (zongertinib): Ruiter G, et al. WCLC 2024. Abs PL04.04
- SOHO-1 (BAY 2927088): Le X, et al. WCLC 2024. Abs PL04.03
- Briefly comment on the eNRGy trial andFDA approval (December 2024) ofzenocutuzumab for advanced, unresectable, or metastatic NSCLC harboring an NRG1 gene fusion. (Schram AM, et al. ESMO 2023. Abs 1315MO; FDA.gov, FDA approves zenocutuzumab for NSCLC)
- How might you incorporate this novel therapy into your clinical practice, and what factors guide your patient selection?
Advertisement
Related to this article
The WVU Heart and Vascular Institute and WVU Cancer Institute performed West Virginia’s first single-port robotic-assisted thoracoscopic lobectomy.
The MHLW approval covers all lines of therapy, including first-line use, in unresectable advanced or recurrent HER2-mutant NSCLC.
UroGen submitted an NDA for UGN-103 in recurrent NMIBC, T-DXd improved PFS in first-line HER2-mutant lung cancer, and more.
Obesity can weaken the immune system and lead to disease progression, but Roswell Park experts revealed that exercise may reverse that effect.
Did you catch all of this week's top oncology news? Test your knowledge with OncLive's Weekly News Quiz.
The oral OMNI-EGFR inhibitor earned fast track status for advanced EGFR C797S–positive non–small cell lung cancer that progressed on a third-generation EGFR TKI.
T-DXd improved PFS in the phase 3 DESTINY-Lung04 trial for first-line HER2-mutant NSCLC.
Phase 3 eVOLVE-Lung02 Trial of First-Line Volrustomig Is Discontinued in First-Line Metastatic NSCLC
The phase 3 eVOLVE-Lung02 trial is being discontinued after its IDMC found volrustomig plus chemotherapy unlikely to meet its dual primary end points.
Advertisement
Advertisement
Trending on OncLive
1
FDA Approves Rusfertide for Polycythemia Vera
2
The OncFive: Top Oncology Articles for the Week of 8/23
3
First-Line Ivonescimab Plus Chemotherapy Meets OS End Point in Advanced Biliary Tract Cancer
4
FDA Approves Daraxonrasib for Metastatic Pancreatic Ductal Adenocarcinoma
5